Jekyll and Hyde: The role of the microenvironment on the progression of cancer

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 163-177

  Allen, Michael ^a   Jones, J Louise ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

angiogenesis; extracellular matrix; hypoxia; inflammation; microenvironment; tumour associated macrophages

Indexed keywords

APRIL PROTEIN; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN LYSINE 6 OXIDASE; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VASCULOTROPIN;

CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CARCINOGENESIS; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HYPOXIA; MYOEPITHELIUM CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TENSILE STRENGTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 78649997911     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2803     Document Type: Review

References (197)

1. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
2. Paget S,. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 571-573.
3. Bissell MJ, Hall HG, Parry G,. How does the extracellular matrix direct gene expression? J Theor Biol 1982; 99: 31-68.
4. Kalluri R, Zeisberg M,. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
5. Orimo A, Gupta PB, Sgroi DC, et al., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
6. Yang F, Tuxhorn JA, Ressler SJ, et al., Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65: 8887-8895.
7. Grotendorst GR, Okochi H, Hayashi N,. A novel transforming growth factor-β response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996; 7: 469-480.
8. Frazier KS, Grotendorst GR,. Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. Int J Biochem Cell Biol 1997; 29: 153-161.
9. Koliopanos A, Friess H, di Mola FF, et al., Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002; 26: 420-427.
10. Wenger C, Ellenrieder V, Alber B, et al., Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 1999; 18: 1073-1080.
11. Olumi AF, Grossfeld GD, Hayward SW, et al., Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011.
12. Bhowmick NA, Chytil A, Plieth D, et al., TGFβ signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-851.
13. Erez N, Truitt M, Olson P, et al., Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 2010; 17: 135-147.
14. Korinek V, Barker N, Moerer P, et al., Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998; 19: 379-383.
15. van de Wetering M, Sancho E, Verweij C, et al., The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250.
16. Vermeulen L, De Sousa EMF, van der Heijden M, et al., Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476.
17. Direkze NC, Jeffery R, Hodivala-Dilke K, et al., Bone marrow-derived stromal cells express lineage-related messenger RNA species. Cancer Res 2006; 66: 1265-1269.
18. Radisky ES, Radisky DC,. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord 2007; 8: 279-287.
19. Fukino K, Shen L, Patocs A, et al., Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. J Am Med Assoc 2007; 297: 2103-2111.
20. Kurose K, Hoshaw-Woodard S, Adeyinka A, et al., Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet 2001; 10: 1907-1913.
21. Moinfar F, Beham A, Friedrich G, et al., Macro-environment of breast carcinoma: frequent genetic alterations in the normal appearing skins of patients with breast cancer. Mod Pathol 2008; 21: 639-646.
22. Patocs A, Zhang L, Xu Y, et al., Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357: 2543-2551.
23. Campbell IG, Qiu W, Polyak K, et al., Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008; 358: 1634-1635; author reply, 1636.
24. Qiu W, Hu M, Sridhar A, et al., No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40: 650-655.
25. Adany R, Iozzo RV,. Altered methylation of versican proteoglycan gene in human colon carcinoma. Biochem Biophys Res Commun 1990; 171: 1402-1413.
26. Hu M, Yao J, Cai L, et al., Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005; 37: 899-905.
27. Hannan MA, Siddiqui Y, Rostom A, et al., Evidence of DNA repair/processing defects in cultured skin fibroblasts from breast cancer patients. Cancer Res 2001; 61: 3627-3631.
28. Schor SL, Schor AM,. Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res 2001; 3: 373-379.
29. Ye S,. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000; 19: 623-629.
30. Hinoda Y, Okayama N, Takano N, et al., Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 2002; 102: 526-529.
31. Holliday DL, Hughes S, Shaw JA, et al., Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 2007; 9: R67.
32. Hunter KW, Crawford NP,. Germ line polymorphism in metastatic progression. Cancer Res 2006; 66: 1251-1254.
33. Nelson CM, Bissell MJ,. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005; 15: 342-352.
34. Jones PL, Jones FS,. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000; 19: 581-596.
35. Chen J, Chen Z, Chen M, et al., Role of fibrillar Tenascin-C in metastatic pancreatic cancer. Int J Oncol 2009; 34: 1029-1036.
36. Katenkamp K, Berndt A, Hindermann W, et al., mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004; 203: 771-779.
37. Carnemolla B, Castellani P, Ponassi M, et al., Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999; 154: 1345-1352.
38. Adams M, Jones JL, Walker RA, et al., Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62: 3289-3297.
39. Wilson KE, Bartlett JM, Miller EP, et al., Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J Cancer 1999; 80: 685-692.
40. Hancox RA, Allen MD, Holliday DL, et al., Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 2009; 11: R24.
41. Meiners S, Powell EM, Geller HM,. Neurite outgrowth promotion by the alternatively spliced region of tenascin-C is influenced by cell-type specific binding. Matrix Biol 1999; 18: 75-87.
42. Sarkar S, Nuttall RK, Liu S, et al., Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 2006; 66: 11771-11780.
43. White ES, Baralle FE, Muro AF,. New insights into form and function of fibronectin splice variants. J Pathol 2008; 216: 1-14.
44. Oyama F, Hirohashi S, Sakamoto M, et al., Coordinate oncodevelopmental modulation of alternative splicing of fibronectin pre-messenger RNA at ED-A, ED-B, and CS1 regions in human liver tumors. Cancer Res 1993; 53: 2005-2011.
45. Serini G, Bochaton-Piallat ML, Ropraz P, et al., The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J Cell Biol 1998; 142: 873-881.
46. Kaczmarek J, Castellani P, Nicolo G, et al., Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994; 59: 11-16.
47. Castellani P, Borsi L, Carnemolla B, et al., Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002; 161: 1695-1700.
48. Kaspar M, Zardi L, Neri D,. Fibronectin as target for tumor therapy. Int J Cancer 2006; 118: 1331-1339.
49. Paszek MJ, Zahir N, Johnson KR, et al., Tensional homeostasis and the malignant phenotype. Cancer Cell 2005; 8: 241-254.
50. Engler AJ, Sen S, Sweeney HL, et al., Matrix elasticity directs stem cell lineage specification. Cell 2006; 126: 677-689.
51. Kagan HM, Li W,. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003; 88: 660-672.
52. Levental KR, Yu H, Kass L, et al., Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
53. Martin LJ, Boyd NF,. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008; 10: 201.
54. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
55. Coussens LM, Fingleton B, Matrisian LM,. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392.
56. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, et al., Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 2008; 68: 2755-2763.
57. Houghton AM, Grisolano JL, Baumann ML, et al., Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 2006; 66: 6149-6155.
58. Nguyen M, Lee MC, Wang JL, et al., The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene 2000; 19: 3449-3459.
59. 2/M arrest, and apoptosis. Exp Cell Res 1998; 241: 394-403.
60. Jones JL, Shaw JA, Pringle JH, et al., Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003; 201: 562-572.
61. Sternlicht MD, Kedeshian P, Shao ZM, et al., The human myoepithelial cell is a natural tumor suppressor. Clin Cancer Res 1997; 3: 1949-1958.
62. Bergstraesser LM, Srinivasan G, Jones JC, et al., Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells. Am J Pathol 1995; 147: 1823-1839.
63. Allinen M, Beroukhim R, Cai L, et al., Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17-32. (Pubitemid 38903159)
64. Papetti M, Herman IM,. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-970.
65. Dor Y, Porat R, Keshet E,. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001; 280: C1367-1374.
66. Zhong H, De Marzo AM, Laughner E, et al., Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
67. Brizel DM, Sibley GS, Prosnitz LR, et al., Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289.
68. Sundfor K, Lyng H, Rofstad EK,. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998; 78: 822-827. (Pubitemid 28418321)
69. Chen CL, Chu JS, Su WC, et al., Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT1, and CAIX. Virchows Arch 2010; 457: 53-61.
70. Carmeliet P, Dor Y, Herbert JM, et al., Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
71. Canning MT, Postovit LM, Clarke SH, et al., Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res 2001; 267: 88-94.
72. Esteban MA, Tran MG, Harten SK, et al., Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66: 3567-3575.
73. Kim JW, Tchernyshyov I, Semenza GL, et al., HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
74. Bindra RS, Schaffer PJ, Meng A, et al., Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann NY Acad Sci 2005; 1059: 184-195.
75. Fukumura D, Xu L, Chen Y, et al., Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001; 61: 6020-6024.
76. Tsuzuki Y, Fukumura D, Oosthuyse B, et al., Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α→ hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000; 60: 6248-6252.
77. Hanahan D, Folkman J,. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
78. Ruan K, Song G, Ouyang G,. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-1062.
79. Shweiki D, Itin A, Soffer D, et al., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
80. Laderoute KR, Alarcon RM, Brody MD, et al., Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res 2000; 6: 2941-2950.
81. Baeriswyl V, Christofori G,. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009; 19: 329-337.
82. Bergers G, Benjamin LE,. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
83. Patel NS, Muneer A, Blick C, et al., Targeting vascular endothelial growth factor in renal cell carcinoma. Tumour Biol 2009; 30: 292-299.
84. Erler JT, Bennewith KL, Nicolau M, et al., Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
85. Pennacchietti S, Michieli P, Galluzzo M, et al., Hypoxia promotes invasive growth by transcriptional activation of the met proto-oncogene. Cancer Cell 2003; 3: 347-361.
86. Jiang YG, Luo Y, He DL, et al., Role of Wnt/β-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1α. Int J Urol 2007; 14: 1034-1039.
87. Csiszar K, Fong SF, Ujfalusi A, et al., Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors. Int J Cancer 2002; 97: 636-642.
88. Kaneda A, Wakazono K, Tsukamoto T, et al., Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004; 64: 6410-6415.
89. Cairns RA, Khokha R, Hill RP,. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003; 3: 659-671.
90. Chang HY, Nuyten DS, Sneddon JB, et al., Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-3743.
91. Chen Y, Shi G, Xia W, et al., Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res 2004; 64: 7302-7310.
92. Payne SL, Fogelgren B, Hess AR, et al., Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 2005; 65: 11429-11436.
93. Solinas G, Germano G, Mantovani A, et al., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-1073.
94. Colotta F, Allavena P, Sica A, et al., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
95. Mantovani A, Romero P, Palucka AK, et al., Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-783.
96. Lin EY, Nguyen AV, Russell RG, et al., Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-740.
97. Qian B, Deng Y, Im JH, et al., A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009; 4: e6562.
98. Ojalvo LS, Whittaker CA, Condeelis JS, et al., Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 2010; 184: 702-712.
99. Hsu HP, Shan YS, Lai MD, et al., Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther 2010; 10.
100. Lewis JS, Landers RJ, Underwood JC, et al., Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol 2000; 192: 150-158.
101. O'Sullivan C, Lewis CE, Harris AL, et al., Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993; 342: 148-149.
102. Lewis CE, Pollard JW,. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612.
103. Mantovani A, Schioppa T, Porta C, et al., Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metast Rev 2006; 25: 315-322.
104. Sica A, Saccani A, Bottazzi B, et al., Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J Immunol 2000; 164: 762-767.
105. Gordon S,. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
106. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-969.
107. Leek RD, Landers RJ, Harris AL, et al., Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999; 79: 991-995.
108. Leek RD, Lewis CE, Whitehouse R, et al., Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625-4629.
109. Murdoch C, Giannoudis A, Lewis CE,. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004; 104: 2224-2234.
110. Lewis CE, Hughes R,. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007; 9: 209.
111. Turner L, Scotton C, Negus R, et al., Hypoxia inhibits macrophage migration. Eur J Immunol 1999; 29: 2280-2287.
112. Burke B, Giannoudis A, Corke KP, et al., Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003; 163: 1233-1243.
113. Burke B, Tang N, Corke KP, et al., Expression of HIF-1α by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196: 204-212.
114. Venneri MA, De Palma M, Ponzoni M, et al., Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-5285.
115. Tsutsui S, Inoue H, Yasuda K, et al., Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006; 98: 261-266.
116. Murdoch C, Tazzyman S, Webster S, et al., Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-7411.
117. Gershon RK, Kondo K,. Infectious immunological tolerance. Immunology 1971; 21: 903-914.
118. Berendt MJ, North RJ,. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980; 151: 69-80.
119. Chakraborty NG, Twardzik DR, Sivanandham M, et al., Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 1990; 145: 2359-2364.
120. Peng L, Kjaergaard J, Plautz GE, et al., Tumor-induced L -selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002; 169: 4811-4821.
121. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201: 779-791.
122. + regulatory T-cells in cancer. Immunol Res 2005; 32: 155-168.
123. Bergamaschi A, Tagliabue E, Sorlie T, et al., Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008; 214: 357-367.
124. Finak G, Bertos N, Pepin F, et al., Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527. (Pubitemid 351655218)
125. Bacac M, Provero P, Mayran N, et al., A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PLoS One 2006; 1: e32.
126. Petty RD, Samuel LM, Murray GI, et al., APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer 2009; 9: 434.
127. Farmer P, Bonnefoi H, Anderle P, et al., A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
128. Damiano JS, Cress AE, Hazlehurst LA, et al., Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
129. Hazlehurst LA, Valkov N, Wisner L, et al., Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 2001; 98: 1897-1903.
130. Weaver VM, Lelievre S, Lakins JN, et al., β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002; 2: 205-216.
131. Kerbel R, Folkman J,. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
132. Ellis LM, Hicklin DJ,. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
133. Hurwitz H, Fehrenbacher L, Novotny W, et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
134. Sandler A, Gray R, Perry MC, et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
135. Miller K, Wang M, Gralow J, et al., Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
136. Mitjans F, Meyer T, Fittschen C, et al., In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int J Cancer 2000; 87: 716-723.
137. Buerkle MA, Pahernik SA, Sutter A, et al., Inhibition of the αv integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86: 788-795.
138. MacDonald TJ, Taga T, Shimada H, et al., Preferential susceptibility of brain tumors to the antiangiogenic effects of an αv integrin antagonist. Neurosurgery 2001; 48: 151-157.
139. Varner JA, Cheresh DA,. Integrins and cancer. Curr Opin Cell Biol 1996; 8: 724-730.
140. Hodivala-Dilke KM, Reynolds AR, Reynolds LE,. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003; 314: 131-144.
141. Nabors LB, Mikkelsen T, Rosenfeld SS, et al., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25: 1651-1657.
142. Chatterjee S, Matsumura A, Schradermeier J, et al., Human malignant glioma therapy using anti-αvβ3 integrin agents. J Neurooncol 2000; 46: 135-144.
143. Taga T, Suzuki A, Gonzalez-Gomez I, et al., αv-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002; 98: 690-697.
144. Eskens FA, Dumez H, Hoekstra R, et al., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur J Cancer 2003; 39: 917-926.
145. Friess H, Langrehr JM, Oettle H, et al., A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 2006; 6: 285.
146. Hariharan S, Gustafson D, Holden S, et al., Assessment of the biological and pharmacological effects of the αvβ3 and αvβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 2007; 18: 1400-1407.
147. Reynolds AR, Hart IR, Watson AR, et al., Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 2009; 15: 392-400.
148. Reardon DA, Akabani G, Coleman RE, et al., Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002; 20: 1389-1397.
149. Silacci M, Brack SS, Spath N, et al., Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 2006; 19: 471-478.
150. Santimaria M, Moscatelli G, Viale GL, et al., Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9: 571-579.
151. Huang X, Molema G, King S, et al., Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-550.
152. Borsi L, Balza E, Carnemolla B, et al., Selective targeted delivery of TNFα to tumor blood vessels. Blood 2003; 102: 4384-4392.
153. Sauer S, Erba PA, Petrini M, et al., Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113: 2265-2274.
154. Brown ER, Charles KA, Hoare SA, et al., A clinical study assessing the tolerability and biological effects of infliximab, a TNFα inhibitor, in patients with advanced cancer. Ann Oncol 2008; 19: 1340-1346.
155. Madhusudan S, Foster M, Muthuramalingam SR, et al., A phase II study of etanercept (Enbrel), a tumor necrosis factor-α inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004; 10: 6528-6534.
156. Richardson PG, Weller E, Lonial S, et al., Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679-686.
157. Schey SA, Morgan GJ, Ramasamy K, et al., The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol 2010; 150: 326-333.
158. Kotla V, Goel S, Nischal S, et al., Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
159. Hagemann T, Lawrence T, McNeish I, et al., 'Re-educating' tumor-associated macrophages by targeting NF-κB. J Exp Med 2008; 205: 1261-1268.
160. Schon M, Wienrich BG, Kneitz S, et al., KINK-1, a novel small-molecule inhibitor of IKKβ, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 2008; 100: 862-875.
161. Bingham CO III, Smugar SS, Wang H, et al., Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology (Oxf) 2009; 48: 1122-1127.
162. Chan FK, Lanas A, Scheiman J, et al., Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179.
163. Bhatt RS, Merchan J, Parker R, et al., A phase 2 pilot trial of low-dose, continuous infusion, or 'metronomic' paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 2010; 116: 1751-1756.
164. Lipton A, Campbell-Baird C, Witters L, et al., Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010; 44: 286-288.
165. Bertagnolli MM, Eagle CJ, Zauber AG, et al., Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 2009; 2: 310-321.
166. Phillips RK, Wallace MH, Lynch PM, et al., A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-860.
167. Mulgrew K, Kinneer K, Yao XT, et al., Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, abegrin. Mol Cancer Ther 2006; 5: 3122-3129.
168. Bhaskar V, Zhang D, Fox M, et al., A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007; 5: 61.
169. Ramakrishnan V, Bhaskar V, Law DA, et al., Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 2006; 5: 273-286.
170. Kabakov AE, Makarova YM, Malyutina YV,. Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17- demethoxygeldanamycin. Int J Radiat Oncol Biol Phys 2008; 71: 858-865.
171. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al., Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
172. Zhu AX, Blaszkowsky LS, Ryan DP, et al., Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903.
173. Xu L, Duda DG, di Tomaso E, et al., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009; 69: 7905-7910.
174. Willett CG, Duda DG, di Tomaso E, et al., Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007; 4: 316-321.
175. Willett CG, Boucher Y, di Tomaso E, et al., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
176. Henry MD, Wen S, Silva MD, et al., A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004; 64: 7995-8001.
177. Ma D, Hopf CE, Malewicz AD, et al., Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006; 12: 2591-2596.
178. Wolf P, Gierschner D, Buhler P, et al., A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol Immunother 2006; 55: 1367-1373.
179. Dornhofer N, Spong S, Bennewith K, et al., Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006; 66: 5816-5827.
180. Kondo S, Tanaka N, Kubota S, et al., Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells. Mol Cancer Ther 2006; 5: 129-137.
181. Giulianelli S, Cerliani JP, Lamb CA, et al., Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: a role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123: 2518-2531.
182. Fischer H, Taylor N, Allerstorfer S, et al., Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008; 7: 3408-3419.
183. Ohuchida K, Mizumoto K, Murakami M, et al., Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004; 64: 3215-3222.
184. Han S, Khuri FR, Roman J,. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006; 66: 315-323.
185. He X, Fang L, Wang J, et al., Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors. Cancer Res 2008; 68: 8678-8686.
186. Guleng B, Tateishi K, Ohta M, et al., Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005; 65: 5864-5871.
187. Takahashi N, Haba A, Matsuno F, et al., Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61: 7846-7854.
188. Loeffler M, Kruger JA, Niethammer AG, et al., Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-1962.
189. Hofheinz RD, al-Batran SE, Hartmann F, et al., Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003; 26: 44-48.
190. Reardon DA, Akabani G, Coleman RE, et al., Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006; 24: 115-122.
191. Hicke BJ, Stephens AW, Gould T, et al., Tumor targeting by an aptamer. J Nucl Med 2006; 47: 668-678.
192. Berkenblit A, Matulonis UA, Kroener JF, et al., A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 2005; 99: 50-57.
193. Rosenbaum E, Zahurak M, Sinibaldi V, et al., Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 2005; 11: 4437-4443.
194. Goffin JR, Anderson IC, Supko JG, et al., Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2005; 11: 3417-3424.
195. Lara PN Jr, Stadler WM, Longmate J, et al., A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006; 12: 1556-1563.
196. Siebels M, Rohrmann K, Oberneder R, et al., A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX((R))) and interferon-α-2a in metastatic renal cell carcinoma patients. World J Urol 2010.
197. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, et al., A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 57-62.